3rd Quarter - Report

CONSTANTINE CANNON, LLP for AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13)

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform

Foreign entity interest: S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform

LobbyistCovered position, as disclosed
STEPHEN S ANDERSON —
W STEPHEN CANNON —
DAVID D GOLDEN New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1249 (112th), S. 23 (112th), S. 27 (112th)

Health Issues HCR

S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act

Foreign entity interest: S. 319 -- drug reimportation H.R. 2 -- healthcare reform bill repeal PDUFA reauthorization; Life sciences research tax credit legislation Orphan drug issues H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act

LobbyistCovered position, as disclosed
STEPHEN S ANDERSON —
W STEPHEN CANNON —
DAVID D GOLDEN New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1423 (112th), H.R. 2632 (112th), S. 1410 (112th), H.R. 2672 (112th), S. 319 (112th), H.R. 2674 (112th), H.R. 2 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.